Earnings Call · Q2 FY2022·2022-08-04

Q2 22EPS +16.39%·Rev n/aQ1 22EPS +26.57%·Rev n/aQ4 21EPS +2.47%·Rev n/aQ3 21EPS +13.15%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Vivian Wu — Investor Relations

Howard W. Robin — President and CEO

Brian Kotzin — Chief Medical Officer

Jonathan Zalevsky — Chief of Research and Development

Jillian Thomsen — Chief Financial Officer

Unknown

−1.1%1d on move date−1.1% vs SPY3d+8.9%5d+8.5%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access